AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Silo Pharma shares surge 13.72% premarket after partnering with Allucent for FDA IND application of SPC-15 PTSD treatment.
ByAinvest
Monday, Nov 17, 2025 8:23 am ET1min read
Silo Pharma (NASDAQ: SILO) surged 13.72% in premarket trading following the announcement of a partnership with Allucent to advance its investigational new drug (IND) application for SPC-15, an intranasal PTSD treatment. The company plans to submit the IND to the FDA in 2026, with first-in-human trials contingent on approval. The partnership, leveraging Allucent’s expertise in regulatory and clinical development, is positioned to streamline SPC-15’s progression via the FDA’s 505(b)(2) accelerated pathway. Anticipated GLP-compliant toxicology and drug-device study data in early 2026 further underscore the program’s potential. The news reinforces Silo’s focus on addressing underserved psychiatric disorders and aligns with its broader strategy of advancing novel therapeutics through strategic collaborations.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet